Plasmid-Based Lassa Virus Reverse Genetics

Area of Science:

• Virology
• Molecular Biology
• Public Health

Background:

• Mammarenaviruses, including Lassa virus (LASV), cause hemorrhagic fevers (HF) with significant morbidity and mortality, particularly in West Africa.
• Current therapeutic options for Lassa fever are limited, with no licensed vaccines available and controversial efficacy of ribavirin.
• Reverse genetics has emerged as a crucial tool for understanding mammarenavirus biology and developing countermeasures.

Purpose of the Study:

• To detail experimental procedures for generating recombinant LASV (rLASV) using advanced plasmid-based reverse genetics.
• To highlight the utility of reverse genetics in studying viral pathogenesis, host interactions, and developing diagnostics and therapeutics.
• To enable research on LASV and other hemorrhagic fever viruses in lower biocontainment settings.

Main Methods:

• Utilizing state-of-the-art plasmid-based reverse genetics systems.
• Generating infectious recombinant mammarenaviruses from cloned cDNAs.
• Employing cell-based minigenome systems to study viral replication and transcription.

Main Results:

• Established protocols for generating rLASV, facilitating in-depth molecular and pathogenesis studies.
• Demonstrated the versatility of reverse genetics for creating LASV variants for drug screening and vaccine development.
• Enabled the generation of single-cycle, reporter-expressing viruses for safer research.

Conclusions:

• Plasmid-based reverse genetics provides a powerful and versatile platform for advancing Lassa fever research.
• These methods are essential for developing novel diagnostics, antivirals, and vaccine candidates against LASV.
• The described techniques facilitate the study of highly pathogenic viruses, potentially in less stringent biocontainment conditions.